Literature DB >> 15008716

Epstein-Barr virus infection in urothelial transitional cell carcinoma tissues.

C K Chuang1, S K Liao.   

Abstract

OBJECTIVE: To explore a possible correlation of Epstein-Barr virus (EBV) infection with urothelial tumours, as the mutation of oncogenes, inactivation of tumour suppressor genes and viral infections may be important in the tumorigenesis of urothelial tumours, and EBV has been implicated in the pathogenesis of a variety of lymphoproliferative disorders and several epithelial neoplasms.
MATERIALS AND METHODS: In all, 104 surgical specimens of transitional cell carcinoma (TCC) were obtained from urological operating rooms, fixed in 10% buffered formalin and processed for in situ hybridization using DNA probes, to locate the signal of EBV-encoded RNAs (EBERs). Immunohistochemistry with antibodies against CD20 and EBV-encoded latent membrane protein-1 (LMP-1) was used on EBER-positive tumour specimens.
RESULTS: Thirty-one tumour specimens were positive for EBER hybridization in 100 evaluable specimens. Of these positive specimens, 21 were positive in both the infiltrating B lymphocytes and TCC tumour cells, seven only in B lymphocytes and three only in TCC cells. Of 31 EBER-positive tumour tissues, 26 (84%) had LMP-1, suggesting that EBER is more sensitive than LMP-1 for detecting EBV infection.
CONCLUSION: There is a strong association between EBV infection and a significant proportion of primary urothelial TCC tumour cells.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15008716     DOI: 10.1111/j.1464-410x.2003.04687.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  1 in total

1.  Role of NRP1 in Bladder Cancer Pathogenesis and Progression.

Authors:  Yang Dong; Wei-Ming Ma; Zhen-Duo Shi; Zhi-Guo Zhang; Jia-He Zhou; Yang Li; Shao-Qi Zhang; Kun Pang; Bi-Bo Li; Wen-da Zhang; Tao Fan; Guang-Yuan Zhu; Liang Xue; Rui Li; Ying Liu; Lin Hao; Cong-Hui Han
Journal:  Front Oncol       Date:  2021-06-23       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.